Authors: | Balachandran, V. P.; DeMatteo, R. P. |
Article Title: | Targeted Therapy for Cancer. The Gastrointestinal Stromal Tumor Model |
Abstract: | Gastrointestinal stromal tumors (GISTs) are unique tumors, arising largely due to oncogenic mutations in KIT or PDGFRA tyrosine kinases. Although surgery remains the most effective treatment, the remarkable clinical success achieved with kinase inhibition has made GIST one of the most successful examples of targeted therapy for the treatment of cancer. The insight gained from this approach has allowed a deeper understanding of the molecular biology driving kinase dependent cancers, and the adaptations to kinase inhibition, linking genotype to phenotype. Mutation tailored kinase inhibition with second generation TKI's, and combination immunotherapy to harness the effects of TKIs remain exciting areas of investigation. © 2013 Elsevier Inc. |
Keywords: | cancer survival; treatment outcome; gene mutation; review; doxorubicin; placebo; sunitinib; dose response; drug efficacy; drug potentiation; nonhuman; cancer adjuvant therapy; gastrointestinal stromal tumor; imatinib; platelet derived growth factor alpha receptor; cancer immunotherapy; genetic association; risk assessment; carcinogenesis; cancer resistance; drug dose escalation; sarcoma; dosage schedule comparison; immunomodulating agent; kit; gastrointestinal surgery; tyrosine kinase; oncogene c kit; molecularly targeted therapy; regorafenib; platelet derived growth factor alpha receptor gene |
Journal Title: | Surgical Oncology Clinics of North America |
Volume: | 22 |
Issue: | 4 |
ISSN: | 1055-3207 |
Publisher: | Elsevier Inc. |
Date Published: | 2013-10-01 |
Start Page: | 805 |
End Page: | 821 |
Language: | English |
DOI: | 10.1016/j.soc.2013.06.001 |
PROVIDER: | scopus |
PUBMED: | 24012400 |
PMCID: | PMC4071221 |
DOI/URL: | |
Notes: | --- - "Export Date: 1 October 2013" - "CODEN: SOCAF" - "Source: Scopus" |